Experience with subcutaneous abatacept for rheumatoid arthritis: An update for clinicians

Therapeutic Advances in Musculoskeletal Disease

Volumn 6, Issue 5, 2014, Pages 159-168

  Khraishi, Majed M ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

abatacept; biologic; costimulation modulator; rheumatoid arthritis; subcutaneous

Indexed keywords

ABATACEPT; CD86 ANTIGEN; INFLIXIMAB; METHOTREXATE; PLACEBO;

AUTOIMMUNITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FLOW CYTOMETRY; HUMAN; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; MORTALITY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 84910086589     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X14551567     Document Type: Review

References (24)

1. Alten R. Kaine J. Keystone E. Nash P. Delaet I. Qi K. et al. (2011) Safety of subcutaneous abatacept in patients with rheumatoid arthritis (RA): Integrated analysis of five clinical trials up to 4.5 years [EULAR abstract #SAT0292]. Ann Rheum Dis 70(Suppl. 3): 617.
2. Becker J. Westhovens R. Hochberg M. Qi K. Kelly S. Smitten A. et al. (2010) The long-term safety of abatacept in the treatment of rheumatoid arthritis: Integrated safety analyses from the abatacept clinical trial program [EULAR abstract #FRI0189]. Ann Rheum Dis 69(Suppl. 3): 377.
3. Bombardier C. Hawker G. Mosher D. (2011) The impact of arthritis in Canada: today and the next 30 years. Toronto, ON: Arthritis Alliance of Canada.
4. Bykerk V. Akhavan P. Hazlewood G. Schieir O. Dooley A. Haraoui B. et al. (2012) Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 39: 1559–1582.
5. Corbo M. Valencia X. Raymond R. Summerill R. Agrawal S. Townsend R. et al. (2009) Subcutaneous administration of abatacept in patients with rheumatoid arthritis: Pharmacokinetics, safety and immunogenicity [EULAR abstract SAT0101]. Ann Rheum Dis 68(Suppl. 3): 574.
6. Genovese M. Becker J. Schiff M. Luggen M. Sherrer Y. Kremer J. et al. (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353: 1114–1123.
7. Genovese M. Covarrubias A. Leon G. Mysler E. Keiserman M. Valente R. et al. (2011) Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 63: 2854–2864.
8. Genovese M. Pacheco-Tena C. Covarrubias A. Leon G. Mysler E. Keiserman M. et al. (2012) Subcutaneous Abatacept: long-term data from the Acquire trial [ACR abstract #462]. Arthritis Rheum 10(Suppl.): S201.
9. Gibofsky A. (2012) Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care 18: S295–S302.
10. Kaine J. Gladstein G. Strusberg I. Robles M. Louw I. Gujrathi S. et al. (2012) Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIIb ALLOW study). Ann Rheum Dis 71: 38–44.
11. Keystone E. Kremer J. Russell A. Box J. Abud-Mendoza C. Elizondo M. et al. (2012) Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis 71: 857–861.
12. Khraishi M. Russell A. Olszynski W. (2010) Safety profile of abatacept in rheumatoid arthritis: a review. Clin Ther 32: 1855–1870.
13. Kremer J. Genant H. Moreland L. Russell A. Emery P. Abud-Mendoza C. et al. (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144: 865–876.
14. Myasoedova E. Crowson C. Kremers H. Therneau T. Gabriel S. (2010) Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum 62: 1576–1582.
15. Nash P. Nayiager S. Genovese M. Kivitz A. Oelke K. Ludivico C. et al. (2013) Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken) 65: 718–728.
16. Scarpato S. Antivalle M. Favalli E. Nacci F. Frigelli S. Bartoli F. et al. (2010) Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford) 49: 289–294.
17. Schiff M. Keiserman M. Codding C. Songcharoen S. Berman A. Nayiager S. et al. (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67: 1096–1103.
18. Schiff M. Alten R. Weinblatt M. Nash P. Fleischmann R. Durez P. et al. (2012) Weekly subcutaneous abatacept confers comparable onset of treatment response and magnitude of efficacy improvement over 6 months when administered with or without an intravenous abatacept loading dose [ACR abstract #2547]. Arthritis Rheum 10(Suppl.): S1076.
19. Schiff M. Weinblatt M. Valente R. van der Heijde D. Citera G. Elegbe A. et al. (2014) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 73: 86–94.
20. Singh J. Furst D. Bharat A. Curtis J. Kavanaugh A. Kremer J. et al. (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64: 625–639.
21. Smolen J. Aletaha D. Bijlsma J. Breedveld F. Boumpas D. Burmester G. et al. (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69: 631–637.
22. Smolen J. Landewé R. Breedveld F. Buch M. Burmester G. Dougados M. et al. (2013) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. DOI: 10.1136/annrheumdis-2013–204573. [Epub ahead of print].
23. Westhovens R. Robles M. Ximenes A. Nayiager S. Wollenhaupt J. Durez P. et al. (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68: 1870–1877.
24. Weinblatt M. Schiff M. Valente R. van der Heijde D. Citera G. Zhao C. et al. (2013) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 65: 28–38.